Literature DB >> 9013955

Conformational transitions in CD4 due to complexation with HIV envelope glycoprotein gp120.

G Denisova1, D Raviv, I Mondor, Q J Sattentau, J M Gershoni.   

Abstract

The binding of the surface envelope glycoprotein gp120 to its receptor, CD4, has been well characterized and is the primary basis for the cell tropism of HIV. In this study, the interaction between recombinant soluble CD4 and native membrane-associated CD4 with gp120 is probed by the use of mAbs. Complexation of gp120 with both forms of CD4 induces conformational epitopes that can be defined with specific mAbs. CG1, CG7, and CG8 are three novel mAbs that have a distinct preference for CD4 complexed over noncomplexed with gp120. The epitopes of these unique mAbs were mapped by cross-inhibition with previously characterized mAbs to a region encompassing the CDR2 and CDR3 loops in domain 1 of CD4. Systematic analysis of CG mAbs binding to CD4 and CD4/gp120 complex delineates a region in the D1 domain of CD4 that undergoes conformational rearrangements upon gp120 binding to its receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9013955

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Characterization of monoclonal antibodies against Escherichia coli core RNA polymerase.

Authors:  Jöelle Rouby; Martine Pugniere; Jean-Claude Mani; Claude Granier; Pierrette Monmouton; Stephane Theulier Saint Germain; Jean-Paul Leonetti
Journal:  Biochem J       Date:  2002-01-15       Impact factor: 3.857

2.  Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.

Authors:  P Kolchinsky; E Kiprilov; J Sodroski
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.

Authors:  P Kolchinsky; E Kiprilov; P Bartley; R Rubinstein; J Sodroski
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Highly conserved beta16/beta17 beta-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding.

Authors:  Alain Mechulam; Martine Cerutti; Martine Pugnière; Dorothée Missé; Johanna Gajardo; Françoise Roquet; James Robinson; Francisco Veas
Journal:  J Mol Med (Berl)       Date:  2005-05-19       Impact factor: 4.599

5.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Constitutive cell surface association between CD4 and CCR5.

Authors:  X Xiao; L Wu; T S Stantchev; Y R Feng; S Ugolini; H Chen; Z Shen; J L Riley; C C Broder; Q J Sattentau; D S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

7.  Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication.

Authors:  P Kolchinsky; T Mirzabekov; M Farzan; E Kiprilov; M Cayabyab; L J Mooney; H Choe; J Sodroski
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

8.  Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.

Authors:  Z Si; M Cayabyab; J Sodroski
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  Purified, soluble recombinant mouse hepatitis virus receptor, Bgp1(b), and Bgp2 murine coronavirus receptors differ in mouse hepatitis virus binding and neutralizing activities.

Authors:  B D Zelus; D R Wessner; R K Williams; M N Pensiero; F T Phibbs; M deSouza; G S Dveksler; K V Holmes
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.

Authors:  N Sullivan; Y Sun; Q Sattentau; M Thali; D Wu; G Denisova; J Gershoni; J Robinson; J Moore; J Sodroski
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.